title: Proteomic analysis of non-small cell lung cancer tissue interstitial fluids.
abstract: BACKGROUND
  Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers, and reliable biomarkers are desirable. The present investigation assesses our ability to identify tumor relevant proteins from NSCLC tissue interstitial fluid (TIF).
  
  
  METHODS
  Paired TIF was collected from three NSCLC patients at the time of surgery, and resolved by two-dimensional gel electrophoresis and in-gel digestion for proteomic analysis. Differentially expressed spots were extracted from the two-dimensional gel and characterized by high-performance liquid chromatography-tandem mass spectrometry. Then, ELISA was used to verify the expression of peroxiredoxin 1 (PRDX1) in TIF of patients with NSCLC and benign lung disease. Finally, the relationship between expression of PRDX1 and clinicopathological features was determined.
  
  
  RESULTS
  Comparative proteomic analysis showed 24 protein spots were differentially expressed with significant changes, including 11 upregulated proteins and 13 downregulated proteins. Of these, PRDX1 was selected for validation in TIF by Western blot and expression of PRDX1 was confirmed to be upregulated in tumor TIF. It was also demonstrated that PRDX1 was significantly elevated in 40 NSCLC patients with a mean level of 36.0 ng/mL compared to 6.26 ng/mL from 20 patients with benign lung disease. A significant correlation was found between the high level of PRDX1 expression and lymph node metastasis and tumor differentiation.
  
  
  CONCLUSIONS
  PRDX1 might be correlated with lymph node metastasis and differentiation, and its elevated expression in TIF may be an adverse biomarker for patients with NSCLC. PRDX1 may be attributed to the malignant transformation of NSCLC, and attention should be paid to a possible target for therapy.
authors.forename: Shaomin
authors.initials: S
authors.lastname: Li
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.forename: Mingxin
authors.initials: M
authors.lastname: Zhang
authors.forename: Lina
authors.initials: L
authors.lastname: Wang
authors.forename: Shaoli
authors.initials: S
authors.lastname: Cheng
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary; D015180:Electrophoresis, Gel, Two-Dimensional; D004797:Enzyme-Linked Immunosorbent Assay; D045604:Extracellular Fluid / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D040901:Proteomics; D053719:Tandem Mass Spectrometry
chemical_list: D014408:Biomarkers, Tumor
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):3974-86
references.pmid: 15930332
references.citation: Anal Chem. 1995 Apr 15;67(8):1426-36
references.pmid: 7741214
references.citation: Mol Cell Proteomics. 2004 Apr;3(4):327-44
references.pmid: 14754989
references.citation: Carcinogenesis. 2003 Apr;24(4):651-7
references.pmid: 12727792
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7004-9
references.pmid: 21487000
references.citation: Free Radic Biol Med. 2011 Jul 15;51(2):299-313
references.pmid: 21558000
references.citation: J Surg Res. 2000 Sep;93(1):108-19
references.pmid: 10945951
references.citation: Mol Cancer Ther. 2010 Apr;9(4):825-32
references.pmid: 20354123
references.citation: FEBS Lett. 2005 May 23;579(13):2873-7
references.pmid: 15876430
references.citation: J Proteome Res. 2011 Mar 4;10(3):1333-42
references.pmid: 21142074
references.citation: Clin Exp Metastasis. 2002;19(4):319-26
references.pmid: 12090472
references.citation: Cancer Sci. 2007 Aug;98(8):1234-40
references.pmid: 17506794
references.citation: Clin Proteomics. 2010 Sep;6(3):75-82
references.pmid: 20930922
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2326-33
references.pmid: 18413821
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5746-54
references.pmid: 17020980
references.citation: Mol Biol Cell. 2010 Sep 1;21(17):2987-95
references.pmid: 20631257
references.citation: Cancer Res. 2011 Mar 1;71(5):1637-46
references.pmid: 21343392
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3875-82
references.pmid: 17606720
references.citation: Proteomics. 2002 Sep;2(9):1156-68
references.pmid: 12362334
references.citation: Histol Histopathol. 2010 Oct;25(10):1297-303
references.pmid: 20712014
references.citation: Genes Dev. 2012 Sep 15;26(18):2001-8
references.pmid: 22987634
references.citation: J Hematol Oncol. 2010 May 02;3:18
references.pmid: 20433767
references.citation: Korean J Intern Med. 2011 Sep;26(3):304-13
references.pmid: 22016591
references.citation: Semin Thromb Hemost. 2003 Oct;29(5):489-97
references.pmid: 14631549
references.citation: PLoS One. 2011;6(9):e25056
references.pmid: 21980378
references.citation: Chest. 2007 Sep;132(3 Suppl):29S-55S
references.pmid: 17873159
references.citation: Mol Oncol. 2010 Feb;4(1):65-89
references.pmid: 20005186
references.citation: Protein Pept Lett. 2009;16(11):1350-9
references.pmid: 20001925